Oncology Corporate Profile
Alligator Bioscience discovers and develops innovative antibody based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients. In the discovery of novel antibody based drugs, Alligator uses its proprietary technology platforms ALLIGATOR-GOLD® and FIND®: ALLIGATOR-GOLD® is a synthetic svFv library containing several billion distinct fully human antibodies. FIND® (Fragment Induced Diversity) is an antibody optimization technology based on single-stranded DNA allowing generation of antibodies with significant clinical benefits.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|ADC-1013||IgG agonistic monoclonal antibody||Various cancer types||I||Janssen|
|ADC-1015||bi-specific immune||Various cancer types||Preclinical||Jansenn|
View additional information on product candidates here »